Finance

Lists
Outlook: 64.3% bullish·14.3% bearish
Go to analysis
RXRX:NASDAQ
Recursion Pharmaceuticals Inc
$3.66
+1.39%
(+0.050) 1D
$3.66
0.00% (0.00)
After hours
Closed: Oct 20, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RXRX...
Open
$3.56
High
$3.67
Low
$3.47
Mkt. cap
2.18B
Avg. vol.
28.04M
Volume
20.93M
52-wk high
$6.70
52-wk low
$2.77
EPS
-$1.04
Beta
1.04
Shares outstanding
596.88M
No. of employees
600
Open
$3.56
High
$3.67
Low
$3.47
Mkt. cap
2.18B
Avg. vol.
28.04M
Volume
20.93M
52-wk high
$6.70
52-wk low
$2.77
EPS
-$1.04
Beta
1.04
Shares outstanding
596.88M
No. of employees
600
News stories
From web sources and news partners
About Recursion Pharmaceuticals Inc
CEONajat Khan
Employees600
Founded2013
HeadquartersSalt Lake City, Utah, United States
SectorBiotechnology
Websiterecursion.com
Analyst ratings
Based on 5 analysts giving stock ratings to RXRX in the past 3 months
Buy
Buy
2
Hold
3
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for RXRX in the last 3 months.
Highest
Current $3.66
$8.00 (+118.58%)
Average
$6.63 (+81.15%)
Lowest
$5.90 (+61.20%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gil Blum
Needham
Buy
Reiterated
$8.00
+118.6%
10/19/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
$5.90
+61.2%
10/16/2026
Alec Stranahan
Bank of America Securities
Hold
Maintained
$6.00
+63.9%
10/16/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
-
-
09/15/2026
Brendan Smith
TD Cowen
Hold
Maintained
-
-
08/05/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
-$0.25 / -$0.23
-6.84%miss
Revenue / Est. (USD)
7.67M / 11.96M
-35.89%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
5.18M
35.54M
6.47M
7.67M
Cost of goods sold
135.75M
110.22M
100.39M
101.10M
Cost of revenue
135.75M
110.22M
100.39M
101.10M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
41.63M
42.17M
34.59M
41.53M
Operating expense
41.63M
42.17M
34.59M
41.53M
Total operating expenses
177.38M
152.39M
134.98M
142.64M
Operating income
-172.20M
-116.85M
-128.50M
-134.97M
Other non operating income
5.24M
-6.03M
784.00K
-1.04M
EBT including unusual items
-162.25M
-108.10M
-122.11M
-131.01M
EBT excluding unusual items
-162.25M
-116.62M
-122.11M
-131.01M
Income tax expense
3.00K
20.00K
-4.60M
-1.00K
Effective tax rate
-
-0.02%
3.77%
-
Other operating expenses
-
-
-
-
Net income
-162.25M
-108.12M
-117.50M
-131.00M
Net profit margin
-3,135.32%
-304.24%
-1,815.57%
-1,708.02%
Earnings per share
-0.36
-0.21
-0.22
-0.25
Interest and investment income
5.54M
6.26M
5.96M
5.31M
Interest expense
-833.00K
-
-350.00K
-309.00K
Net interest expenses
4.71M
6.26M
5.61M
5.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-151.16M
-97.37M
-108.83M
-116.80M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps